Business Context and Reporting Period
This Form 8-K Current Report was filed by Arvinas, Inc. on February 15, 2024. The report discloses significant changes in the company's executive leadership, specifically regarding the Chief Financial Officer role.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: Sean Cassidy indicated his resignation as Chief Financial Officer, Treasurer, and principal financial officer, effective February 29, 2024, to pursue another professional opportunity.
- Interim Appointment: The Board of Directors appointed Randy Teel, Ph.D., as interim Chief Financial Officer, Treasurer, and principal financial officer, effective February 29, 2024.
- Continued Roles: Dr. Teel will continue serving as Senior Vice President, Corporate and Business Development, overseeing corporate strategy, business development, investor relations, and communications.
Guidance, Outlook, and Management Commentary
The company is currently undertaking a search to identify a permanent Chief Financial Officer. Dr. Teel will not receive additional compensation for assuming the interim roles, and no changes will be made to his existing employment agreement. He will continue to participate in current company benefit plans. The filing notes there are no family relationships between Dr. Teel and other directors or officers, nor any undisclosed material interests.
Investor Verification Checklist
- Confirm the exact effective date of Sean Cassidy's departure (February 29, 2024).
- Verify the timeline for the search and appointment of a permanent Chief Financial Officer.
- Review Dr. Teel's background in biopharmaceutical strategy and risk management to assess interim leadership stability.
- Monitor future filings for any changes to the company's financial reporting or strategic direction under new leadership.